{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:34:57Z","timestamp":1790922897997,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Deanship of Graduate Studies and Scientific Research at Jouf University","award":["DGSSR-2025-FC-01022"],"award-info":[{"award-number":["DGSSR-2025-FC-01022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-33006-6","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:47:12Z","timestamp":1766494032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In-silico studies, synthesis, and pharmacological screening of novel multitarget diphenylpyrazole scaffold as EGFR\/BRAF and cyclooxygenase-2 inhibitors"],"prefix":"10.1038","volume":"16","author":[{"given":"Mohamed A.","family":"Abdelgawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed N. A.","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed H.","family":"Elkomy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Elmowafy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab M.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arafa","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Sadek","family":"Abdel-Bakky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Farouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A. H.","family":"Elshemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa G. Safi","family":"El-Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"33006_CR1","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1245\/s10434-022-12151-6","volume":"29","author":"SVS Deo","year":"2022","unstructured":"Deo, S. V. S., Sharma, J. & Kumar, S. GLOBOCAN 2020 report on global cancer burden: challenges and opportunities for surgical oncologists. Ann. Surg. Oncol. 29, 6497\u20136500 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"33006_CR2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2147\/OTT.S149428","volume":"11","author":"L Tang","year":"2018","unstructured":"Tang, L. et al. Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: A meta-analysis. Onco Targets Ther. 11, 1055\u20131066 (2018).","journal-title":"Onco Targets Ther."},{"key":"33006_CR3","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.3390\/ijms12074465","volume":"12","author":"FF Cai","year":"2011","unstructured":"Cai, F. F. et al. Epigenetic therapy for breast cancer. Int. J. Mol. Sci. 12, 4465\u20134476 (2011).","journal-title":"Int. J. Mol. Sci."},{"key":"33006_CR4","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita","year":"2008","unstructured":"DeVita, V. T. & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643\u20138653 (2008).","journal-title":"Cancer Res."},{"key":"33006_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12272-018-1098-z","volume":"42","author":"WY Kim","year":"2019","unstructured":"Kim, W. Y. Therapeutic targeting of lipid synthesis metabolism for selective elimination of cancer stem cells. Arch. Pharm. Res. 42, 25\u201339 (2019).","journal-title":"Arch. Pharm. Res."},{"key":"33006_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1053\/j.seminoncol.2015.09.029","volume":"42","author":"E Zanardi","year":"2015","unstructured":"Zanardi, E., Bregni, G., De Braud, F. & Di Cosimo, S. Better together: targeted combination therapies in breast cancer. Semin Oncol. 42, 887\u2013895 (2015).","journal-title":"Semin Oncol."},{"key":"33006_CR7","doi-asserted-by":"publisher","first-page":"R283","DOI":"10.1530\/ERC-17-0425","volume":"25","author":"TV Augusto","year":"2018","unstructured":"Augusto, T. V., Georgina, C. S., Rodrigues, C. M. P., Teixeira, N. & Amaral, C. Acquired resistance to aromatase inhibitors: where we stand! Endocr. Relat. Cancer. 25, R283\u2013R301 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"33006_CR8","doi-asserted-by":"publisher","first-page":"113064","DOI":"10.1016\/j.biopha.2022.113064","volume":"150","author":"X Li","year":"2022","unstructured":"Li, X. et al. The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine. Biomed. Pharmacotherapy. 150, 113064 (2022).","journal-title":"Biomed. Pharmacotherapy"},{"key":"33006_CR9","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari, R. B. et al. Combination therapy in combating cancer. Oncotarget 8, 38022\u201338043 (2017).","journal-title":"Oncotarget"},{"key":"33006_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer. 4, 253\u2013265 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"33006_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/CAD.0000000000000464","volume":"28","author":"A Kumar","year":"2016","unstructured":"Kumar, A., Sharma, P. R. & Mondhe, D. M. Potential anticancer role of colchicine-based derivatives: an overview. Anticancer Drugs. 28, 250\u2013262 (2016).","journal-title":"Anticancer Drugs"},{"key":"33006_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2174\/0929867329666220729152741","volume":"30","author":"C Pecoraro","year":"2022","unstructured":"Pecoraro, C., Carbone, D., Cascioferro, S. M., Parrino, B. & Diana, P. Multi or Single-Kinase inhibitors to counteract drug resistance in cancer: what is new? Curr. Med. Chem. 30, 776\u2013782 (2022).","journal-title":"Curr. Med. Chem."},{"key":"33006_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/path.3018","volume":"226","author":"T Lechertier","year":"2012","unstructured":"Lechertier, T. & Hodivala-Dilke, K. Focal adhesion kinase and tumour angiogenesis. J. Pathol. 226, 404\u2013412 (2012).","journal-title":"J. Pathol."},{"key":"33006_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1369\/0022155414561498","volume":"63","author":"H Yoon","year":"2015","unstructured":"Yoon, H., Dehart, J. P., Murphy, J. M. & Lim, S. T. S. Understanding the roles of FAK in cancer: Inhibitors, genetic Models, and new insights. J. Histochem. Cytochem. 63, 114\u2013128 (2015).","journal-title":"J. Histochem. Cytochem."},{"key":"33006_CR15","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.21873\/anticanres.14494","volume":"40","author":"G Li Petri","year":"2020","unstructured":"Li Petri, G. et al. New imidazo[2,1-b][1,3,4]thiadiazole aerivatives anhibit FAK phosphorylation and potentiate the antiproliferative effects of gemcitabine through modulation of the human equilibrative nucleoside transporter-1 in peritoneal mesothelioma. Anticancer Res. 40, 4913\u20134919 (2020).","journal-title":"Anticancer Res."},{"key":"33006_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK signaling in human cancer as a target for therapeutics. Pharmacol. Ther. 146, 132\u2013149 (2015).","journal-title":"Pharmacol. Ther."},{"key":"33006_CR17","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders. Eur J. Med. Chem 276, 116678 (2024).","DOI":"10.1016\/j.ejmech.2024.116678"},{"key":"33006_CR18","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.1021\/acs.jmedchem.6b00487","volume":"59","author":"GR Ott","year":"2016","unstructured":"Ott, G. R. et al. Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK). J. Med. Chem. 59, 7478\u20137496 (2016).","journal-title":"J. Med. Chem."},{"key":"33006_CR19","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1517\/13543776.2014.948845","volume":"24","author":"E Shanthi","year":"2014","unstructured":"Shanthi, E. et al. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: A patent review. Expert Opin. Ther. Pat. 24, 1077\u20131100 (2014).","journal-title":"Expert Opin. Ther. Pat."},{"key":"33006_CR20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones, S. F. et al. A phase i study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest. New. Drugs. 33, 1100\u20131107 (2015).","journal-title":"Invest. New. Drugs"},{"key":"33006_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","volume":"33","author":"J Mendelsohn","year":"2006","unstructured":"Mendelsohn, J. & Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 33, 369\u2013385 (2006).","journal-title":"Semin Oncol."},{"key":"33006_CR22","first-page":"263","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig, S. L. & Osimertinib First Global Approval Drugs 76, 263\u2013273 (2016).","journal-title":"First Global Approval Drugs"},{"key":"33006_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","volume":"15","author":"Y Shi","year":"2020","unstructured":"Shi, Y. et al. Clinical Activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation. J. Thorac. Oncol. 15, 1015\u20131026 (2020). Safety.","journal-title":"J. Thorac. Oncol."},{"key":"33006_CR24","first-page":"91","volume":"7","author":"PN Tran","year":"2016","unstructured":"Tran, P. N. & Klempner, S. J. Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer. Lung Cancer: Targets Therapy. 7, 91\u201397 (2016).","journal-title":"Lung Cancer: Targets Therapy"},{"key":"33006_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","volume":"12","author":"CC Ho","year":"2017","unstructured":"Ho, C. C. et al. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J. Thorac. Oncol. 12, 567\u2013572 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"33006_CR26","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.jtho.2017.07.017","volume":"12","author":"A Bearz","year":"2017","unstructured":"Bearz, A., De Carlo, E., Doliana, R., Schiappacassi, M. & Acquired BRAF V600E mutation as resistant mechanism after treatment with Third-Generation EGFR tyrosine kinase inhibitor. J. Thorac. Oncol. 12, e181\u2013e182 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"33006_CR27","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M. & Watson, I. R. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 37, 3183\u20133199 (2018).","journal-title":"Oncogene"},{"key":"33006_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten, F. R. & Grivennikov, S. I. Inflammation and cancer: Triggers, Mechanisms, and consequences. Immunity 51, 27\u201341 (2019).","journal-title":"Immunity"},{"key":"33006_CR29","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer. 13, 759\u2013771 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"33006_CR30","doi-asserted-by":"publisher","first-page":"67904","DOI":"10.18632\/oncotarget.18958","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget 8, 67904\u201367917 (2017).","journal-title":"Oncotarget"},{"key":"33006_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","volume":"1","author":"ER Rayburn","year":"2009","unstructured":"Rayburn, E. R., Ezell, S. J. & Zhang, R. Anti-inflammatory agents for cancer therapy. Mol. Cell. Pharmacol. 1, 29\u201343 (2009).","journal-title":"Mol. Cell. Pharmacol."},{"key":"33006_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr1648","volume":"9","author":"C Chavey","year":"2007","unstructured":"Chavey, C. et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 9, 1\u201311 (2007).","journal-title":"Breast Cancer Res."},{"key":"33006_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21072605","volume":"21","author":"S Zappavigna","year":"2020","unstructured":"Zappavigna, S. et al. Anti-inflammatory drugs as anticancer agents. Int. J. Mol. Sci. 21, 1\u201329 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"33006_CR34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.7150\/ijbs.7.651","volume":"7","author":"BF Zamarron","year":"2011","unstructured":"Zamarron, B. F. & Chen, W. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 7, 651\u2013658 (2011).","journal-title":"Int. J. Biol. Sci."},{"key":"33006_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ejca.2006.01.013","volume":"42","author":"L Yan","year":"2006","unstructured":"Yan, L., Anderson, G. M., DeWitte, M. & Nakada, M. T. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur. J. Cancer. 42, 793\u2013802 (2006).","journal-title":"Eur. J. Cancer"},{"key":"33006_CR36","first-page":"5","volume":"7","author":"S Kraus","year":"2011","unstructured":"Kraus, S. & Arber, N. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Curr. Colorectal Cancer Rep. 7, 5\u20137 (2011).","journal-title":"Curr. Colorectal Cancer Rep."},{"key":"33006_CR37","first-page":"1","volume":"3","author":"AG Denkova","year":"2020","unstructured":"Denkova, A. G., Liu, H., Men, Y. & Eelkema, R. Enhanced cancer therapy by combining radiation and chemical effects mediated by nanocarriers. Adv. Ther. (Weinh). 3, 1\u201317 (2020).","journal-title":"Adv. Ther. (Weinh)"},{"key":"33006_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24262\/jmd.2.2.17008","volume":"2","author":"A Mittal","year":"2017","unstructured":"Mittal, A., Dixit, S. & Rana, S. Anticancer effects of chemotherapy and nature products. J. Med. Discovery. 2, 1\u20138 (2017).","journal-title":"J. Med. Discovery"},{"key":"33006_CR39","first-page":"27","volume":"2396","author":"J Bailey","year":"2011","unstructured":"Bailey, J., Oliveri, A. & Levin, E. Regulation of inflammation in cancer by eicosanoids Emily. Prostaglandins Other Lipid Mediat. 2396, 27\u201336 (2011).","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"33006_CR40","doi-asserted-by":"crossref","unstructured":"Sharma, V. et al. Recent advancement in the discovery and development of COX-2 inhibitors: Insight into biological activities and SAR studies (2008\u20132019) Vrinda. Bioorg Chem,\u00a0103007, (2019).","DOI":"10.1016\/j.bioorg.2019.103007"},{"key":"33006_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bcp.12801","volume":"81","author":"M Ruzov","year":"2016","unstructured":"Ruzov, M., Rimon, G., Pikovsky, O. & Stepensky, D. Celecoxib interferes to a limited extent with aspirin-mediated Inhibition of platelets aggregation. Br. J. Clin. Pharmacol. 81, 316\u2013326 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"33006_CR42","doi-asserted-by":"publisher","first-page":"21268","DOI":"10.18632\/aging.203443","volume":"13","author":"D Yin","year":"2021","unstructured":"Yin, D. et al. Celecoxib reverses the glioblastoma chemo-resistance to Temozolomide through mitochondrial metabolism. Aging 13, 21268\u201321282 (2021).","journal-title":"Aging"},{"key":"33006_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.arcmed.2005.11.014","volume":"37","author":"V Vital-Reyes","year":"2006","unstructured":"Vital-Reyes, V. et al. Celecoxib inhibits cellular Growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch. Med. Res. 37, 689\u2013695 (2006).","journal-title":"Arch. Med. Res."},{"key":"33006_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-9966-27-66","volume":"27","author":"W Park","year":"2008","unstructured":"Park, W., Oh, Y. T., Han, J. H. & Pyo, H. Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2. J. Experimental Clin. Cancer Res. 27, 1\u20139 (2008).","journal-title":"J. Experimental Clin. Cancer Res."},{"key":"33006_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2867-12-53","volume":"12","author":"ZJ Dai","year":"2012","unstructured":"Dai, Z. J. et al. Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell. Int. 12, 1\u20138 (2012).","journal-title":"Cancer Cell. Int."},{"key":"33006_CR46","doi-asserted-by":"publisher","first-page":"508","DOI":"10.18632\/oncotarget.28747","volume":"16","author":"S Shyamsunder","year":"2025","unstructured":"Shyamsunder, S., Lu, Z., Takiar, V. & Waltz, S. E. Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: insights into RTK dependent and independent mechanisms. Oncotarget 16, 508\u2013530 (2025).","journal-title":"Oncotarget"},{"key":"33006_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-017-0457-z","volume":"17","author":"T Notarangelo","year":"2017","unstructured":"Notarangelo, T., Sisinni, L., Condelli, V. & Landriscina, M. Dual EGFR and BRAF Blockade overcomes resistance to Vemurafenib in BRAF mutated thyroid carcinoma cells. Cancer Cell. Int. 17, 1\u20139 (2017).","journal-title":"Cancer Cell. Int."},{"key":"33006_CR48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s13277-012-0324-4","volume":"33","author":"YX Wang","year":"2012","unstructured":"Wang, Y. X., Gao, J. X., Wang, X. Y., Zhang, L. & Liu, C. M. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. Tumour Biol. 33, 957\u2013966 (2012).","journal-title":"Tumour Biol."},{"key":"33006_CR49","doi-asserted-by":"crossref","unstructured":"Kang, J. H. et al. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 11, 334 (2011).","DOI":"10.1186\/1471-2407-11-334"},{"key":"33006_CR50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cllc.2013.04.006","volume":"14","author":"SI Rothschild","year":"2013","unstructured":"Rothschild, S. I. & Gautschi, O. Crizotinib in the treatment of non-small-cell lung cancer. Clin. Lung Cancer. 14, 473\u2013480 (2013).","journal-title":"Clin. Lung Cancer"},{"key":"33006_CR51","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.2147\/OTT.S165511","volume":"11","author":"T Akamine","year":"2018","unstructured":"Akamine, T., Toyokawa, G., Tagawa, T. & Seto, T. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. Onco Targets Ther. 11, 5093\u20135101 (2018).","journal-title":"Onco Targets Ther."},{"key":"33006_CR52","doi-asserted-by":"crossref","unstructured":"Santos, N. E., Carreira, A. R. F., Silva, V. L. M. & Braga, S. S. Natural and biomimetic antitumor pyrazoles, a perspective. Molecules 25(6), 1364 (2020).","DOI":"10.3390\/molecules25061364"},{"key":"33006_CR53","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/ajhp\/zxz329","volume":"77","author":"K Roubal","year":"2020","unstructured":"Roubal, K., Myint, Z. W., Kolesar, J. M. & Erdafitinib A novel therapy for FGFR-mutated urothelial cancer. Am. J. Health-System Pharm. 77, 346\u2013351 (2020).","journal-title":"Am. J. Health-System Pharm."},{"key":"33006_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bioorg.2018.03.014","volume":"78","author":"MF Harras","year":"2018","unstructured":"Harras, M. F. & Sabour, R. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma. Bioorg. Chem. 78, 149\u2013157 (2018).","journal-title":"Bioorg. Chem."},{"key":"33006_CR55","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/JU.0000000000000443","volume":"202","author":"K Fizazi","year":"2019","unstructured":"Fizazi, K. et al. Re: darolutamide in nonmetastatic, castration-resistant prostate cancer. J. Urol. 202, 660\u2013661 (2019).","journal-title":"J. Urol."},{"key":"33006_CR56","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ejmech.2018.02.033","volume":"148","author":"LY Li","year":"2018","unstructured":"Li, L. Y. et al. Potent hydrazone derivatives targeting esophageal cancer cells. Eur. J. Med. Chem. 148, 359\u2013371 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR57","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1021\/acsomega.7b01512","volume":"3","author":"S Patil","year":"2018","unstructured":"Patil, S., Kuman, M. M., Palvai, S., Sengupta, P. & Basu, S. Impairing powerhouse in colon cancer cells by Hydrazide-Hydrazone-Based small molecule. ACS Omega. 3, 1470\u20131481 (2018).","journal-title":"ACS Omega"},{"key":"33006_CR58","first-page":"1","volume":"26","author":"CM Interactions","year":"2021","unstructured":"Interactions, C. M. et al. Synthesis of new Naphthyl aceto Hydrazone-Based metal complexes: micellar Interactions, DNA Binding, Antimicrobial, and cancer Inhibition studies. Molecules 26, 1\u201318 (2021).","journal-title":"Molecules"},{"key":"33006_CR59","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1021\/tx900111y","volume":"22","author":"C Fan","year":"2009","unstructured":"Fan, C., Zhao, J., Zhao, B., Zhang, S. & Miao, J. Novel complex of copper and a salicylaldehyde pyrazole hydrazone derivative induces apoptosis through up-regulating integrin \u03b24 in vascular endothelial cells. Chem. Res. Toxicol. 22, 1517\u20131525 (2009).","journal-title":"Chem. Res. Toxicol."},{"key":"33006_CR60","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1021\/jm2013248","volume":"55","author":"J Bostr\u00f6m","year":"2012","unstructured":"Bostr\u00f6m, J., Hogner, A., Llin\u00e0s, A., Wellner, E. & Plowright, A. T. Oxadiazoles in medicinal chemistry. J. Med. Chem. 55, 1817\u20131830 (2012).","journal-title":"J. Med. Chem."},{"key":"33006_CR61","first-page":"853","volume":"126","author":"PR Helft","year":"2016","unstructured":"Helft, P. R., Slaven, J. E., Cottingham, A. H., Ma, M. A. R. & Torke, A. M. Design, synthesis, Docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors Md. Eur. J. Med. Chem. 126, 853\u2013869 (2016).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR62","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ejmech.2011.11.015","volume":"47","author":"K Liu","year":"2012","unstructured":"Liu, K., Lu, X., Zhang, H. J., Sun, J. & Zhu, H. L. Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents. Eur. J. Med. Chem. 47, 473\u2013478 (2012).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR63","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.bmcl.2008.03.057","volume":"18","author":"R Ruel","year":"2008","unstructured":"Ruel, R. et al. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor. Bioorg. Med. Chem. Lett. 18, 2985\u20132989 (2008).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"33006_CR64","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1016\/j.bmcl.2011.08.022","volume":"21","author":"H Rajak","year":"2011","unstructured":"Rajak, H. et al. 2,5-Disubstituted-1,3,4-oxadiazoles\/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid-based histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 21, 5735\u20135738 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"33006_CR65","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1021\/jm500303u","volume":"57","author":"S Valente","year":"2014","unstructured":"Valente, S. et al. 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells. J. Med. Chem. 57, 6259\u20136265 (2014).","journal-title":"J. Med. Chem."},{"key":"33006_CR66","doi-asserted-by":"crossref","unstructured":"Ihmaid, S. K. et al. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7\/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability. Bioorg Chem 111, 104835 (2021).","DOI":"10.1016\/j.bioorg.2021.104835"},{"key":"33006_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00149","volume":"8","author":"CA Kunos","year":"2018","unstructured":"Kunos, C. A. & Ivy, S. P. Triapine radiochemotherapy in advanced stage cervical cancer. Front. Oncol. 8, 1\u20137 (2018).","journal-title":"Front. Oncol."},{"key":"33006_CR68","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.ejmech.2009.12.048","volume":"45","author":"CD Fan","year":"2010","unstructured":"Fan, C. D. et al. A novel copper complex of salicylaldehyde pyrazole hydrazone induces apoptosis through up-regulating integrin \u03b24 in H322 lung carcinoma cells. Eur. J. Med. Chem. 45, 1438\u20131446 (2010).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR69","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.bioorg.2016.02.007","volume":"65","author":"A Kamal","year":"2016","unstructured":"Kamal, A. et al. Combretastatin linked 1,3,4-oxadiazole conjugates as a potent tubulin polymerization inhibitor. Bioorg. Chem. 65, 126\u2013136 (2016).","journal-title":"Bioorg. Chem."},{"key":"33006_CR70","doi-asserted-by":"crossref","unstructured":"Rejmund, M. et al. Piperazinyl fragment improves anticancer activity of triapine. PLoS One 13(4), e0188767 (2018).","DOI":"10.1371\/journal.pone.0188767"},{"key":"33006_CR71","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jhet.3118","volume":"55","author":"LS Pavase","year":"2018","unstructured":"Pavase, L. S., Mane, D. V. & Baheti, K. G. Anti-inflammatory exploration of sulfonamide containing diaryl pyrazoles with promising COX-2 selectivity and enhanced gastric safety profile. J. Heterocycl. Chem. 55, 913\u2013922 (2018).","journal-title":"J. Heterocycl. Chem."},{"key":"33006_CR72","doi-asserted-by":"crossref","unstructured":"Abdelrahman, K. S. et al. Development and Assessment of 1,5\u2013Diarylpyrazole\/Oxime Hybrids Targeting EGFR and JNK\u20132 as Antiproliferative Agents: A Comprehensive Study through Synthesis, Molecular Docking, and Evaluation. Molecules, 28, (2023).","DOI":"10.3390\/molecules28186521"},{"key":"33006_CR73","first-page":"1789","volume":"53","author":"HC Shen","year":"2011","unstructured":"Shen, H. C. & Hammock, B. D. Discovery of inhibitors of soluble epoxide hydrolase: A target with multiple potential therapeutic indications. J. Med. Chem. 53, 1789\u20131808 (2011).","journal-title":"J. Med. Chem."},{"key":"33006_CR74","doi-asserted-by":"publisher","first-page":"112662","DOI":"10.1016\/j.ejmech.2020.112662","volume":"205","author":"AH Abdelazeem","year":"2020","unstructured":"Abdelazeem, A. H. et al. Discovery of novel urea-diarylpyrazole hybrids as dual COX-2\/sEH inhibitors with improved anti-inflammatory activity and highly reduced cardiovascular risks. Eur. J. Med. Chem. 205, 112662 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR75","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Maldonado, E. A. et al. Synthesis, characterization and biological activity of schiff bases based on Chitosan and acetyl acetophenone and 2-phenyl-2-acetophenone derivatives: experimental and theoretical approach. J Mol. Struct 1326, 141079 (2025).","DOI":"10.1016\/j.molstruc.2024.141079"},{"key":"33006_CR76","unstructured":"Inci, G. H., Cem, Y., Synthesis of potential anticancer & effective compounds containing pyrazole \u2013 benzensulfonamide moieties, enlightenment of their structures and their cytotoxic activities. WO2019\/17857, 2019, A2 (2019)."},{"key":"33006_CR77","doi-asserted-by":"publisher","first-page":"13645","DOI":"10.3390\/molecules181113645","volume":"18","author":"G Dou","year":"2013","unstructured":"Dou, G. et al. Clean and efficient synthesis of isoxazole derivatives in aqueous media. Molecules 18, 13645\u201313653 (2013).","journal-title":"Molecules"},{"key":"33006_CR78","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14756366.2018.1457657","volume":"33","author":"MS Mohamed","year":"2018","unstructured":"Mohamed, M. S., Mansour, Y. E., Amin, H. K. & El-Araby, M. E. Molecular modelling insights into a physiologically favourable approach to eicosanoid biosynthesis Inhibition through novel thieno[2,3-b]pyridine derivatives. J. Enzyme Inhib. Med. Chem. 33, 755\u2013767 (2018).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"33006_CR79","doi-asserted-by":"publisher","first-page":"22917","DOI":"10.1039\/C6RA02168A","volume":"6","author":"XY Lu","year":"2016","unstructured":"Lu, X. Y. et al. Design, synthesis and evaluation of benzenesulfonamide-substituted 1,5-diarylpyrazoles containing phenylacetohydrazide derivatives as COX-1\/COX-2 agents against solid tumors. RSC Adv. 6, 22917\u201322935 (2016).","journal-title":"RSC Adv."},{"key":"33006_CR80","unstructured":"Animal Cell Culture Guide. Atcc (2014)."},{"key":"33006_CR81","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi, C. & Nicoletti, I. Analysis of apoptosis by Propidium iodide staining and flow cytometry. Nat. Protoc. 1, 1458\u20131461 (2006).","journal-title":"Nat. Protoc."},{"key":"33006_CR82","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/pst.426","volume":"10","author":"JL Sebaugh","year":"2011","unstructured":"Sebaugh, J. L. \u00c3. Guidelines for accurate EC50 \/ IC50 Estimation. Pharm. Stat. 10, 128\u2013134 (2011).","journal-title":"Pharm. Stat."},{"key":"33006_CR83","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1080\/14756366.2018.1503654","volume":"33","author":"MK AbdElhameid","year":"2018","unstructured":"AbdElhameid, M. K., Labib, M. B., Negmeldin, A. T., Al-Shorbagy, M. & Mohammed, M. R. Design, synthesis, and screening of ortho-amino thiophene Carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors. J. Enzyme Inhib. Med. Chem. 33, 1472\u20131493 (2018).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"33006_CR84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bioorg.2017.09.009","volume":"75","author":"AH Abdelazeem","year":"2017","unstructured":"Abdelazeem, A. H. et al. Novel Diphenylthiazole derivatives with multi-target mechanism: Synthesis, Docking study, anticancer and anti-inflammatory activities. Bioorg. Chem. 75, 127\u2013138 (2017).","journal-title":"Bioorg. Chem."},{"key":"33006_CR85","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ejmech.2018.07.024","volume":"156","author":"HAM El-Sherief","year":"2018","unstructured":"El-Sherief, H. A. M. et al. Synthesis, anticancer activity and molecular modeling studies of 1,2,4-triazole derivatives as EGFR inhibitors. Eur. J. Med. Chem. 156, 774\u2013789 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR86","doi-asserted-by":"publisher","first-page":"14845","DOI":"10.1074\/jbc.M606695200","volume":"282","author":"JK Slack-davis","year":"2007","unstructured":"Slack-davis, J. K. et al. Cellular characterization of a novel focal adhesion. J. Biol. Chem. 282, 14845\u201314852 (2007).","journal-title":"J. Biol. Chem."},{"key":"33006_CR87","doi-asserted-by":"crossref","unstructured":"Long, Z. et al. Design, synthesis and biological evaluation of 4-arylamino-pyrimidine derivatives as focal adhesion kinase inhibitors. Bioorg Chem 140, 106792 (2023).","DOI":"10.1016\/j.bioorg.2023.106792"},{"key":"33006_CR88","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes, N. E., Lane, H. A. & Miescher, F. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer. 5, 341\u2013354 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"33006_CR89","doi-asserted-by":"crossref","unstructured":"Abou-Zied, H. A., Youssif, B. G. M., Mohamed, M. F. A., Hayallah, A. M. & Abdel-Aziz, M. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and Docking studies of novel Xanthine derivatives carrying chalcone moiety as hybrid molecules. Bioorg Chem 89, 102997 (2019).","DOI":"10.1016\/j.bioorg.2019.102997"},{"key":"33006_CR90","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejmech.2019.05.015","volume":"176","author":"M Hisham","year":"2019","unstructured":"Hisham, M., Youssif, B. G. M., Osman, E. E. A., Hayallah, A. M. & Abdel-Aziz, M. Synthesis and biological evaluation of novel Xanthine derivatives as potential apoptotic antitumor agents. Eur. J. Med. Chem. 176, 117\u2013128 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR91","doi-asserted-by":"crossref","unstructured":"Arora, R. et al. Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor. Eur J. Med. Chem 250, (2023).","DOI":"10.1016\/j.ejmech.2023.115231"},{"key":"33006_CR92","doi-asserted-by":"crossref","unstructured":"Al-Wahaibi, L. H. et al. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAFV600E dual inhibitors. Bioorg Chem 104, 104260(2020).","DOI":"10.1016\/j.bioorg.2020.104260"},{"key":"33006_CR93","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejmech.2017.05.006","volume":"136","author":"Z Cui","year":"2017","unstructured":"Cui, Z. et al. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. Eur. J. Med. Chem. 136, 372\u2013381 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR94","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bioorg.2017.12.013","volume":"76","author":"HAM El-Sherief","year":"2018","unstructured":"El-Sherief, H. A. M., Youssif, B. G. M., Bukhari, S. N. A., Abdel-Aziz, M. & Abdel-Rahman, H. M. Novel 1,2,4-triazole derivatives as potential anticancer agents: Design, synthesis, molecular Docking and mechanistic studies. Bioorg. Chem. 76, 314\u2013325 (2018).","journal-title":"Bioorg. Chem."},{"key":"33006_CR95","doi-asserted-by":"crossref","unstructured":"Ramadan, M. et al. Design and synthesis of new pyranoquinolinone heteroannulated to Triazolopyrimidine of potential apoptotic antiproliferative activity. Bioorg Chem 105, 104392 (2020).","DOI":"10.1016\/j.bioorg.2020.104392"},{"key":"33006_CR96","doi-asserted-by":"publisher","unstructured":"Karag\u00fcl, M. \u0130., Akta\u015f, S., Yetkin, D., Bayrak, G. & \u00c7elikcan, D. P53, Bcl2 and Bax Expression and Apoptosis in Perifosine and Vitamin D-Treated Endometrial Cancer Cell Line (HEC1A). in 1564MDPI AG, (2018). https:\/\/doi.org\/10.3390\/proceedings2251564","DOI":"10.3390\/proceedings2251564"},{"key":"33006_CR97","doi-asserted-by":"publisher","first-page":"8057","DOI":"10.1021\/jm801107u","volume":"51","author":"G Smith","year":"2008","unstructured":"Smith, G. et al. Design, synthesis, and biological characterization of a caspase 3\/7 selective Isatin labeled with 2-[18f]fluoroethylazide. J. Med. Chem. 51, 8057\u20138067 (2008).","journal-title":"J. Med. Chem."},{"key":"33006_CR98","doi-asserted-by":"crossref","unstructured":"Abdelall, E. K. A., Elshemy, A. H., Labib, H. & Mohamed, E. A. M. B. F. Characterization of novel heterocyclic compounds based on 4-aryl-4H-chromene scaffold as anticancer agents: Design, synthesis, antiprofilerative activity against resistant cancer cells, dual \u03b2-tubulin\/c-Src inhibition, cell cycle arrest and apoptosis induction. Bioorg Chem 120, 105591 (2022).","DOI":"10.1016\/j.bioorg.2021.105591"},{"key":"33006_CR99","doi-asserted-by":"publisher","first-page":"W159","DOI":"10.1093\/nar\/gkac394","volume":"50","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. CB-Dock2: improved protein-ligand blind Docking by integrating cavity detection, Docking and homologous template fitting. Nucleic Acids Res. 50, W159\u2013W164 (2022).","journal-title":"Nucleic Acids Res."},{"key":"33006_CR100","doi-asserted-by":"publisher","first-page":"W5","DOI":"10.1093\/nar\/gkab255","volume":"49","author":"G Xiong","year":"2021","unstructured":"Xiong, G. et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49, W5\u2013W14 (2021).","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"33006_CR101","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1080\/07391102.2020.1824814","volume":"40","author":"BK Kumar","year":"2022","unstructured":"Kumar, B. K. et al. Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. J. Biomol. Struct. Dyn. 40 (3), 1363\u20131386 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"33006_CR102","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bmcl.2008.10.107","volume":"19","author":"S Sidique","year":"2009","unstructured":"Sidique, S. et al. Design and synthesis of pyrazole derivatives as potent and selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP). Bioorg. Med. Chem. Lett. 19, 222\u2013225 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"33006_CR103","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1016\/j.bmcl.2015.05.059","volume":"25","author":"N Bechmann","year":"2015","unstructured":"Bechmann, N. et al. Novel (pyrazolyl)benzenesulfonamides with a nitric oxide-releasing moiety as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. 25, 3295\u20133300 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"33006_CR104","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2174\/138527211794519005","volume":"15","author":"JY Yoon","year":"2011","unstructured":"Yoon, J. Y., Lee, S. & Shin, H. Recent advances in the regioselective synthesis of pyrazoles. Curr. Org. Chem. 15, 657\u2013674 (2011).","journal-title":"Curr. Org. Chem."},{"key":"33006_CR105","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ejmech.2015.09.021","volume":"103","author":"HS Ibrahim","year":"2015","unstructured":"Ibrahim, H. S. et al. Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII. Eur. J. Med. Chem. 103, 583\u2013593 (2015).","journal-title":"Eur. J. Med. Chem."},{"key":"33006_CR106","doi-asserted-by":"crossref","unstructured":"Abdelazeem, A. H. et al. Discovery of novel urea-diarylpyrazole hybrids as dual COX-2\/sEH inhibitors with improved anti-inflammatory activity and highly reduced cardiovascular risks. Eur J. Med. Chem 205, 112662 (2020).","DOI":"10.1016\/j.ejmech.2020.112662"},{"key":"33006_CR107","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1021\/acsmedchemlett.0c00278","volume":"11","author":"J He","year":"2020","unstructured":"He, J. et al. Synthesis, biological Evaluation, and molecular Docking of arylpyridines as antiproliferative agent targeting tubulin. ACS Med. Chem. Lett. 11, 1611\u20131619 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"33006_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules24183387","volume":"24","author":"NN Cob-Calan","year":"2019","unstructured":"Cob-Calan, N. N. et al. Molecular Docking and dynamics simulation of protein \u03b2-tubulin and antifungal Cyclic lipopeptides. Molecules 24, 1\u201310 (2019).","journal-title":"Molecules"},{"key":"33006_CR109","doi-asserted-by":"publisher","first-page":"103144","DOI":"10.1016\/j.arabjc.2021.103144","volume":"14","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Molecular description of pyrimidine-based inhibitors with activity against FAK combining 3D-QSAR analysis, molecular Docking and molecular dynamics. Arab. J. Chem. 14, 103144 (2021).","journal-title":"Arab. J. Chem."},{"key":"33006_CR110","doi-asserted-by":"publisher","first-page":"32442","DOI":"10.1021\/acsomega.2c03951","volume":"7","author":"M Shi","year":"2022","unstructured":"Shi, M. et al. Molecular Docking, molecular dynamics Simulations, and free energy calculation insights into the binding mechanism between VS-4718 and focal adhesion kinase. ACS Omega. 7, 32442\u201332456 (2022).","journal-title":"ACS Omega"},{"key":"33006_CR111","doi-asserted-by":"crossref","unstructured":"Yang, H. et al. Design, synthesis, biological evaluation and molecular docking of novel F-18-labeled focal adhesion kinase inhibitors as potential tumor radiotracers. Molecules, 29, (2024).","DOI":"10.3390\/molecules29061224"},{"key":"33006_CR112","doi-asserted-by":"crossref","unstructured":"Osama, M. et al. Hiroyuki Konno, Design, synthesis, and Biological Evaluation of Novel 1,5-diarylpyrazole Carboxamides with Dual Inhibition of EGFR and COX-2 for the Treatment of Cancer and Inflammatory Diseases, Bioorg Med Chem Lett., 130, 130416 (2025).","DOI":"10.1016\/j.bmcl.2025.130416"},{"key":"33006_CR113","doi-asserted-by":"crossref","unstructured":"Elshibani, F. A. et al. GC-MS and HPLC chemical profile, antioxidant, anti-acetylcholinesterase, and anti-diabetic activities of Libyan Salvia lanigera herb extract and essential oil. Sci Rep. 15(1), 31853 (2025).","DOI":"10.1038\/s41598-025-12233-x"},{"key":"33006_CR114","doi-asserted-by":"publisher","first-page":"e07875","DOI":"10.1016\/j.heliyon.2021.e07875","volume":"7","author":"A Ritika","year":"2021","unstructured":"Ritika, A. et al. In Silico prediction, characterization and molecular Docking studies on Glutathione-S-transferase as a molecular sieve for toxic agrochemicals explored in survey of North Indian farmers. Heliyon 7, e07875 (2021).","journal-title":"Heliyon"},{"key":"33006_CR115","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1039\/C7MD00381A","volume":"8","author":"R De Ferreira","year":"2017","unstructured":"De Ferreira, R. & Schapira, M. A systematic analysis of atomic protein-ligand interactions in the PDB. Medchemcomm 8, 1970\u20131981 (2017).","journal-title":"Medchemcomm"},{"key":"33006_CR116","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1006\/jmbi.2000.4473","volume":"307","author":"M Brandl","year":"2001","unstructured":"Brandl, M., Weiss, M. S., Jabs, A., S\u00fchnel, J. & Hilgenfeld, R. C-H\u00b7\u00b7\u00b7\u03c0-interactions in proteins. J. Mol. Biol. 307, 357\u2013377 (2001).","journal-title":"J. Mol. Biol."},{"key":"33006_CR117","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1021\/cr300222d","volume":"113","author":"AS Mahadevi","year":"2013","unstructured":"Mahadevi, A. S. & Sastry, G. N. Cation-\u03c0 interaction: its role and relevance in chemistry, biology, and material science. Chem. Rev. 113, 2100\u20132138 (2013).","journal-title":"Chem. Rev."},{"key":"33006_CR118","doi-asserted-by":"publisher","first-page":"183","DOI":"10.33945\/SAMI\/JCR.2019.3.3","volume":"1","author":"HSH Mohamed","year":"2019","unstructured":"Mohamed, H. S. H. & Ahmed, S. A. Reviewing of synthesis and computational studies of Pyrazolo pyrimidine derivatives. J. Chem. Reviews. 1, 183\u2013232 (2019).","journal-title":"J. Chem. Reviews"},{"key":"33006_CR119","doi-asserted-by":"crossref","unstructured":"Obakiro, S. B. et al. Phytochemical, Cytotoxicity, and Antimycobacterial Activity Evaluation of Extracts and Compounds from the Stem Bark of Albizia coriaria Welw ex. Oliver. Evidence-based Complementary and Alternative Medicine,\u00a02022. (2022).","DOI":"10.1155\/2022\/7148511"},{"key":"33006_CR120","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1021\/acsomega.0c01581","volume":"5","author":"NA Dur\u00e1n-Iturbide","year":"2020","unstructured":"Dur\u00e1n-Iturbide, N. A., D\u00edaz-Eufracio, B. I. & Medina-Franco, J. L. In Silico ADME\/Tox profiling of natural products: A focus on BIOFACQUIM. ACS Omega. 5, 16076\u201316084 (2020).","journal-title":"ACS Omega"},{"key":"33006_CR121","doi-asserted-by":"publisher","unstructured":"Adem, \u015e., Y\u0131rt\u0131c\u0131, \u00dc., Ayd\u0131n, M., Rawat, R. & Ey\u00fcpo\u011flu, V. Natural flavonoids as promising 6-phosphogluconate dehydrogenase inhibitor candidates: in Silico and in vitro assessments. Arch. Pharm. (Weinheim). 1\u201314. https:\/\/doi.org\/10.1002\/ardp.202300326 (2023).","DOI":"10.1002\/ardp.202300326"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33006-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33006-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33006-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:02:51Z","timestamp":1768478571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33006-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33006"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33006-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1973"}}